Table 2.
Baseline characteristics of included studies.
| Study (first author, year) | Study design | Intervention | Delivery system | Follow-up | CRS phenotype | Age, ya (hyper/iso) | Female, n (hyper/iso) | Male, n (hyper/iso) | TNP |
|---|---|---|---|---|---|---|---|---|---|
| Dawood 2022 | RCT, open label | Hypertonic saline (2.3%) | High pressure/ Low volume | 7, 14, and 21 days | CRSsNP | N/A | N/A | N/A | 40 |
| Low 2014 | RCT, double blind | Hypertonic saline (2.7%) | Low-pressure/ High volume | 7, 21, and 45 days | CRSwNP and CRSsNP | 40.4/41.5 | 8/10 | 13/12 | 43 |
| Padiyar 2018 | RCT, open label | Hypertonic saline (3.0%) | Low-pressure/ High volume | 7, 15, and 30 days | CRSwNP | 34.9/34.33 | 10/12 | 20/18 | 60 |
| Tripathy 2019 | RCT, open label | Hypertonic saline (3.0%) | Low pressure/ High volume | 7, 15, and 30 days | CRSwNP and CRSsNP | 36.4/36.8 | 14/12 | 16/18 | 60 |
| Vakil 2019 | RCT, open label | Hypertonic saline (3.0%) | Low pressure/ High volume | 7, 21, and 45 days | CRSwNP and CRSsNP | 34.9/34.33 | 32/36 | 46/42 | 156 |
| Wang 2020 | RCT, double blind | Hypertonic saline (2.0%) | High pressure/ low volume | 2, 8, 16, and 24 weeks | CRSwNP | 40.78/41.80 | 17/16 | 31/29 | 93 |
| Wiikmann 2002 | RCT, double blind | Hypertonic saline (2.0%) | Low pressure/ LHigh volume | 7 and 30 days | CRSwNP and CRSsNP | N/A | N/A | N/A | 27 |
CRS, Chronic Rhinosinusitis; CRSsNP, Chronic Rhinosinusitis without Nasal Polyps; CRSwNP, Chronic Rhinosinusitis with Nasal Polyps; FESS, Functional Endoscopic Sinus Surgery; Hyper, Hypertonic saline; Iso, Isotonic saline; TNP, Total Number of Patients.
a
Mean.